Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Perspectives on Accelerating Successful Implementation of Artificial Intelligence in Biopharma and Healthcare
0
Zitationen
5
Autoren
2025
Jahr
Abstract
Artificial intelligence (AI) and large language models (LLMs) promise to reshape discovery, development, and commercialization across the biopharmaceutical value chain. Yet adoption remains uneven, marked by fragmented pilots, governance constraints, and wide variation in organizational readiness. To address these challenges, this study applies diffusion-of-innovation theory and human-centered service-design principles to investigate two questions: (1) What is the current status of AI and LLM implementation in the biopharmaceutical industry? (RQ1) and (2) Which collaborative structures and organizational designs enable scalable, value-generating AI platforms? (RQ2). The study employs a mixed-methods approach that integrates a narrative synthesis of peer-reviewed and industry literature (2020−2025) with six semi-structured interviews involving leaders in drug development, clinical operations, MedTech, and digital strategy. Triangulating across published evidence, organizational practice, and expert experience allows the analysis to surface cross-cutting patterns that would not appear through a single-method design. Findings reveal a multi-speed diffusion pattern: rapid adoption in discovery and document generation, slower progress in clinical and regulatory settings, and emerging use cases in manufacturing and commercialization. Interview insights highlight persistent obstacles—risk-tiered governance, data-validation gaps, and workflow misalignment—alongside enablers such as platform partnerships, venture-client models, regulatory consortia, and startup co-development. Human-centered workflow design, biologically grounded analytics, and transparent governance consistently emerged as essential for moving AI from isolated experimentation to enterprise-level capability. This paper contributes a unified framework that clarifies the current state of AI and LLM adoption in biopharma and identifies the organizational and ecosystem mechanisms required for responsible, scalable implementation. By linking external collaborative structures with internal governance, data, and workflow designs, the study offers a practical, conceptually-grounded blueprint for transitioning from pilots to enterprise-level transformation.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.436 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.311 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.753 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.523 Zit.